Piotr Wysocki: Liver resection vs nonsurgical treatments in patients with early multinodular hepatocellular cancer
Piotr Wysocki recently posted on LinkedIn:
“Current Barcelona Clinic Liver Cancer guidelines do not support liver resection (LR) for HCC patients with 2 or 3 nodules that are each 3 cm or smaller.
In a retrospective cohort study, Italian researchers used data from HE.RC.O.LE.S (liver resection) and ITA.LI.CA. (percutaneous radiofrequency ablation – PRFA and transarterial chemoembolization – TACE) databases. A matching-adjusted indirect comparison (MAIC) method was applied to balance data and potential confounding factors between the 3 groups.
The analysis included data from 720 patients with early multinodular HCC, of whom 296 underwent LR, 240 PRFA, and 184 TACE (n: 184).
The 1-, 3 and 5-year survival rates of patients undergoing particular treatment were as follows:
- LR – 89.1%, 70.9%, 56.4%
- PRFA – 94.0, 65.2%, 39.9%
- TACE – 90.9%, 48.9%, 29.2%
The outcomes of HCC patients undergoing LR were significantly better compared to PRFA or TACE-treated patients:
- PRFA vs LR – HR=1.41; 95% CI, 1.07-1.86; P = .01
- TACE vs LR – HR=1.86; 95% CI, 1.29-2.68; P = .001.”
Source: Piotr Wysocki/LinkedIn
Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.
His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.
Read other posts by Piotr Wysocki published on OncoDaily.